摘要
目的:研讨优甲乐对妊娠期亚临床甲状腺功能减退症(甲减)患者母婴结局的影响。方法:选取2018年1月至2021年3月收入我院的妊娠期亚临床甲减患者76例,按随机数字表法分为两组,每组38例。对照组予以甲状腺素片治疗,观察组施加优甲乐治疗,比较两组的甲状腺激素水平以及母婴结局。结果:观察组患者的治疗总有效率显著优于对照组(P<0.05);观察组患者治疗后TSH显著低于对照组(P<0.05);两组患者治疗后的FT3、FT4差异无统计学意义(P>0.05);与对照组比较,观察组产妇并发症发生率明显下降,差异有统计学意义(P<0.05);观察组产妇并发症发生率与围生儿不良结局发生率均显著低于对照组(P<0.05)。结论:对妊娠期亚临床甲减患者实施优甲乐治疗,能够有效改善患者的甲状腺功能,减少产妇并发症发生率,改善母婴结局,值得临床推广。
Objective:To investigate the effect of Youjiale on maternal and infant outcomes and thyroid function of patients with subclinical hypothyroidism(HYPOthyroidism).Methods:Seventy-six patients with subclinical hypothyroidism during pregnancy admitted to our hospital from January 2018 to March 2021 were selected and divided into two groups according to random number table method,with 38 patients in each group.The control group was treated with thyroxine tablets,and the observation group was treated with Youjiale.The thyroid hormone levels and maternal and infant outcomes of the 2 groups were compared.Results:The total effective rate of observation group was significantly better than control group(P<0.05).TSH in the observation group was significantly lower than that in the control group after treatment(P<0.05).There was no significant difference in FT3 and FT4 between the 2 groups after treatment(P>0.05).Compared with the control group,the incidence of maternal complications in the observation group was significantly decreased,and the difference between the 2 groups was statistically significant(P<0.05).The incidence of maternal complications and perinatal adverse outcomes in the observation group were significantly lower than those in the control group(P<0.05).Conclusion:Youjiale can effectively improve thyroid function,reduce the incidence of maternal complications,and improve maternal and infant outcomes in patients with subclinical hypothyroidism during pregnancy,which is worthy of clinical promotion.
作者
余映华
梅晓慧
颜惠芳
YU Yinghua;MEI Xiaohui;YAN Huifang(Department of Obstetrics,Nanjing Lishui District People’s Hospital,Nanjing 211200,China)
出处
《临床与病理杂志》
CAS
2022年第2期394-397,共4页
Journal of Clinical and Pathological Research
